News/ News/ R&D Sanofi builds case for Toujeo in younger type 1 diabetics Phil Taylor Diabetes, insulin, Lantus, Sanofi, Toujeo, type 1 diabetes 0 Comment Sanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but Share X Sanofi builds case for Toujeo in younger type 1 diabetics https://pharmaphorum.com/news/sanofi-builds-case-for-toujeo-in-younger-type-1-diabetics/
Diabetes/ News/ News/ News/ Novo Nordisk/ Patients/ R&D/ Top pharmaceutical companies/ Top stories Real-world diabetes study CONFIRMs positive comparative efficacy for Novo’s Tresiba Piotr Wnuk Diabetes, Novo Nordisk, Sanofi, Toujeo, Tresiba 0 Comment Novo Nordisk presented the latest results for its diabetes injectable Tresiba last weekend. These demonstrated significantly better control Share X Real-world diabetes study CONFIRMs positive comparative efficacy for Novo’s Tresiba https://pharmaphorum.com/news/tresiba-improved-sugar-control-decreased-hypos/
Diabetes, insulin, Lantus, Sanofi, Toujeo, type 1 diabetes
0 Comment
